New drugs for pulmonary hypertension - horizon scanning review

Record ID 32002000854
Authors' objectives:

To summarise the current research evidence on new drugs for pulmonary hypertension (PH).

Authors' recommendations: - Clinical impact The continuing development of national specialist services for pulmonary hypertension will lead to an increasing number of patients (both primary and secondary PH) being diagnosed and therefore considered for long-term therapy. Based on research evidence the selected use of prostacyclin or endothelin receptor antagonist therapy should increase clinical benefits and prolong survival. - Service impact These therapies need to be initiated and monitored within specialist services. The national designation of 4 UK specialist centres for the management of PH is ongoing. Any consequent increase in the number of patients being referred for diagnosis and management will have long-term implications for the level, access and costs of future service provision. - Patient issues Because of the significantly reduced quality and length of life associated with pulmonary hypertension there will be pressure from patients and their carers to consider long-term prostacyclin or endothelin receptor antagonist therapy. - Financial and overall NHS impact Although the number of patients with PPH is small there are a growing number of people diagnosed with secondary PH. The cost of treatment is high. Use in other types of PH is likely to increase. Non-drug service costs are also high.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
URL for published report:
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Costs and Cost Analysis
  • Hypertension, Pulmonary
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: National Horizon Scanning Centre
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.